Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 9, Issue 2, 2008, Pages 96-102

  Vieitez, Paula ^a   Gómez, Oscar ^b   Uceda, Esther R ^c   Vera, María Eugenia ^a   Molina Holgado, Eduardo ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Paraplegic National Hospital   (Spain)

^c NASA AMES RESEARCH CENTER   (United States)

Author keywords

Angiotensin receptor blockers; Diabetic Nephropathy glomeruli; Growth factors; Renin angiotensin system

Indexed keywords

ANGIOTENSIN II; IRBESARTAN; ISOPHANE INSULIN; PLATELET DERIVED GROWTH FACTOR B; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG MECHANISM; GLOMERULUS; IMMUNOHISTOCHEMISTRY; KIDNEY INJURY; MALE; NONHUMAN; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STATISTICAL SIGNIFICANCE; STREPTOZOCIN DIABETES; SYSTEMIC THERAPY; UNINEPHRECTOMY; WESTERN BLOTTING;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BIPHENYL COMPOUNDS; BLOTTING, WESTERN; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; IMMUNOHISTOCHEMISTRY; KIDNEY GLOMERULUS; MALE; PLATELET-DERIVED GROWTH FACTOR; RATS; RATS, SPRAGUE-DAWLEY; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 47349095149     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2008.018     Document Type: Article

References (43)

1. Ioannou GN, Bryson CL, Boyko EJ. Prevalence and trends of insulin resistance, impaired fasting glucose and diabetes. J Diabetes Complications 2007;21:363-70.
2. Marshall SM. Recent advances in diabetic nephropathy. Clin Med 2004;4:277-82.
3. Steffes MW, Bilous RW, Sutherland DE et al. Cell and matrix components of the glomerular mesangium in type I diabetes. Diabetes 1992;41:679-84.
4. Ichinose K, Kawasaki E, Eguchi K. Recent advancement of understanding pathogenesis of type 1 diabetes and potential relevance to diabetic nephropathy. Am J Nephrol 2007;27:554-64.
5. Weir MR. Effects of renin-angiotensin system inhibition end-organ protection: can we do better? Clin Ther 2007;29:1803-24.
6. Karalliedde J, Viberti G. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes. J Hum Hypertens 2006;20:239-53.
7. Lee EY, Shim MS, Kim MJ et al. Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes. Exp Mol Med 2004;36:65-70.
8. Kang YS, Park YG, Kim BK et al. Angiotensin II stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes. J Mol Endocrinol 2006;36:377-88.
9. Pimentel JL Jr, Sundell CL, Wang S et al. Role of angiotensin II in the expression and regulation of transforming growth factor-beta in obstructive nephropathy. Kidney Int 1995;48:1233-46.
10. Kagami S, Border WA, Miller DE et al. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431-7.
11. Ziyadeh FN. Mediators of diabetic renal disease: the case of TGF-β as the major mediator. J Am Soc Nephrol 2004;15(suppl 1):S55-S57.
12. Reeves WB, Andreoli TE. Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc Natl Acad Sci USA 2000; 97:7667-9.
13. Fraser D, Wakefield L, Phillips A. Independent regulation of transforming growth factor beta 1 transcription and translation by glucose and platelet derived growth factor. Am J Pathol 2002; 161:1039-49.
14. Yamabe H, Osawa H, Kaizuka M et al. Platelet derived growth factor, basic fibroblast growth factor, and interferon gamma increase type IV collagen production in human fetal mesangial cells via a transforming growth factor beta dependent mechanism. Nephrol Dial Transplant 2000; 15:872-6.
15. Kalantarinia K, Awad AS, Siragy EM. Urinary and renal interstitial concentrations of TNF-α increase prior to the rise in albuminuria in diabetic rats. Kidney Int 2003;64:1208-13.
16. Cooper ME, Vranes D, Youssef S et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-R in experimental diabetes. Diabetes 1999;48:2229-39.
17. Siragy EM, Awad A, Abadir P et al. The angiotensin II type 1 receptor mediates renal interstitial content of tumor necrosis factor-α in diabetic rats. Endocrinology 2003; 144:2229-33.
18. Cohen MP, Chen S, Ziyadeh FN et al. Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria and diabetic nephropathy. Kidney International 2005; 68:1554-61.
19. Flyvbjerg A, Mogensen CE, Osterby R et al. Renal hypertrophy in experimental diabetes. J Diabet Complications 1991;5:62-4.
20. Seyer-Hansen K. Renal hypertrophy in Streptozotocin diabetic rats. Clin Sci Mol Med 1976;51:551-5.
21. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilising the principle of protein dye binding. Anal Biochem 1976;72:248-54.
22. 1C assay. Clin Lab 1993; 39:991-6.
23. Schlondorff D, Roczniak S, Satriano JA et al. Prostaglandin synthesis by isolated rat glomeruli: effect of angiotensin II. J Am J Physiol 1980;239:F486-F495.
24. González-Albarrán O, Gómez O, Ruiz E et al. Role of systolic blood pressures on the progression of kidney damage in an experimental model of type 2 diabetes mellitus, obesity and hypertension (Zucker rats). Am J Hypertens 2003;16:979-85.
25. Rossing P, Parving HH, Zeeuw D. Renoprotection by blocking the RAAS in diabetic nephropathy - fact or fiction? Nephron Dial Transplant 2006;21:2354-7.
26. Lewis EJ, Hunsicker LG, Clarke WR et al. Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes. New Engl J Med 2001;345:851-60.
27. Kasiske BL, Kalil RS, Ma JZ et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: A metaregression analysis. Ann Intern Med 1993;118:129-38.
28. Timmermans PB, Wong PC, Chiu AT et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45:205-51.
29. Matsusaka T, Hymes J, Ichikawa I. Angiotensin in progressive renal disease: Theory and practice. J Am Soc Nephrol 1996; 7:2025-43.
30. Wolf G, Neilson EG. Angiotensin II as a renal growth factor. J Am Soc Nephrol 1993;3:1531-40.
31. Gross ML, El-Shakmak A, Szabo A et al. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia 2003;46:856-68.
32. Allard J, Buléon M, Cellier E et al. ACE Inhibitor reduces growth factor receptor expression and signaling but also albuminuria through B2-kinin glomerular reception activation in diabetic rats. Am J Physiol Renal Physiol 2007;293:F1083-F1092.
33. Kitamura M, Ishikawa Y, Konta T. Explanted glomeruli: Utility and limitations. Exp Nephrol 2001;9:349-54.
34. Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7.
35. Adamis AP, Miller JW, Bernal MT et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118:445-50.
36. Marshall SM. The podocyte: a potential therapeutic target in diabetic nephropathy? Curr Pharm Des 2007;13:2713-20.
37. Liu E, Morimoto M, Kitajima S. Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. J Am Soc Nephrol 2007;18:2094-104.
38. Navarro JF, Milena FJ, Mora C et al. Tumor necrosis factor-α gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int 2005;68(suppl 99): S98-S102.
39. Sugimoto H, Shikata K, Wada J et al. Advanced glycation end products cytokine nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumor necrosis factor-α and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia 1999;42:878-86.
40. Fukui M, Nakamura T, Ebihara I et al. Effects of enalapril on endothelin 1 and growth factor gene expression in diabetic rat glomeruli. J Lab Clin Med 1994;123:763-8.
41. Muller DN, Shagdarsuren E, Park JK et al. Immunosuppressive treatment protects against angiotensin II induced renal damage. Am J Pathol 2002;161:1679-93.
42. Chu SC, Tsai CH, Yang SF et al. Induction of vascular endothelial growth factor gene expression by proinflammatory cytokines in human pulp and gingival fibroblasts. J Endod 2004;30:704-07.
43. Ryuto M, Ono M, Izumi H et al. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem 1996;271:28220-8.